Clinical assessment of azapropazone in rheumatoid arthritis
- 1 January 1976
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 4 (1) , 44-49
- https://doi.org/10.1185/03007997609109280
Abstract
SummaryAzapropazone was investigated in a 2-week double-blind clinical out-patient trial against placebo in 23 patients with definite rheumatoid arthritis. The drug was given at a dose of 1200 mg. per day before food. At this dose level the drug was shown to have an antirheumatic effect in terms of pain relief, articular tenderness and duration of morning stiffness.Keywords
This publication has 16 references indexed in Scilit:
- Death after Taking MedicamentsBMJ, 1974
- Observations on Drug Prescribing in Rheumatoid ArthritisBMJ, 1974
- Preliminary clinical evaluation of azapropazone in rheumatoid arthritisCurrent Medical Research and Opinion, 1974
- Method for Assessing Therapeutic Potential of Anti-inflammatory Antirheumatic Drugs in Rheumatoid ArthritisBMJ, 1973
- Evaluation Of A Functional Index In Rheumatoid ArthritisScandinavian Journal of Rheumatology, 1973
- The evaluation of antirheumatic drugsCurrent Medical Research and Opinion, 1973
- The action of azapropazone, oxyphenbutazone and phenylbutazone on lysosomesJournal of Pharmacy and Pharmacology, 1971
- Salicylate Therapy in Rheumatoid ArthritisJAMA, 1965
- Generalization from Pain of Various Types and Diverse OriginsScience, 1959
- MEASUREMENT OF DIGITAL SWELLING IN RHEUMATOID ARTHRITISThe Lancet, 1951